Developer of the Investigational Portable Neuromodulation Stimulator (PoNS®) Treatment

Helius Medical Technologies is a United States-based medical device company developing and commercializing the PoNS® Treatment platform, a specially patterned stimulation technology with the clinical evidence to treat balance and gait disorders in patients with traumatic brain injury (TBI) and chronic neurological disease. The first targeted application of the PoNS® is for chronic balance deficit due to mild to moderate TBI.

Risk Factors

Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks are discussed more fully in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2017, which we filed with the SEC on March 12, 2018. These risks include the following: risks related to the Company’s limited operating history; the Company being dependent on the ability and expertise of its Chief Executive Officer, Chief Medical Officer and a very limited number of employees; the Company having incurred losses since its inception and its anticipation that it will continue to incur substantial net losses for the foreseeable future and may never achieve or sustain profitability; risks related to the Company’s limited operating history; the Company’s dependence on outside scientists and third-party research institutions for its research and development in order to be able to commercialize its product candidates; the risk that if the Company fails to obtain FDA clearance for commercialization of or otherwise fails to ensure that the PoNS® device is available for purchase by the U.S. Government by December 31, 2021, the Company will be subject to significant risk of loss of data and proprietary rights and a US$2,000,000 contract by December 31, 2018 penalty payable to A&B pursuant to the Strategic Agreement with A&B; the risk that the Strategic Agreement with A&B may be terminated; risks related to the limited market awareness of the Company and its product; risks related to the neuromodulation market being new and growing but undefined; the Company’s PoNS® technology being a new “untested” form of neurostimulation therapy and the medical community tending to be very conservative in adopting new therapies; risks related to the Company needing to expand its products beyond its single product by commercializing new product candidates, and the Company not being able to do so in a timely fashion and at expected costs, or at all; and development by others of new or improved devices or products that may result in the Company’s present and future products from becoming obsolete.

COMPANY HIGHLIGHTS

✓ Potential first in class, investigational non-invasive PoNS® technology addressing symptoms of neurological disease or trauma
✓ Positive clinical data in large registrational trial for first indication
✓ Clear regulatory pathway (de novo to 510k in US), contemporaneous submissions to US, Canada, Australia, Europe and China
✓ Multiple large, underserved markets the first of which is Traumatic Brain Injury (TBI) - a $5Billion+ indication in the US alone, PoNS would be first and only product indicated for balance disorder related to TBI
✓ Well characterized commercialization model through initial workers compensation and disability focus expanding to full commercial coverage
✓ Significant barriers to competitor entry with comprehensive IP portfolio
✓ Potential to generate revenue in 2018

Indication and Target Patient Population - US*

- Traumatic Brain Injury (5M patients)
- Multiple Sclerosis (1M patients)
- Cerebral Palsy (764K patients)
- Stroke (7M patients; 795K new each year)
- PTSD (25M patients)
- Facial Nerve Palsy (75K patients)
- Depression (15.7M patients)
- Parkinson’s Disease (1M patients; 60K new each year)

PoNS® CLINICAL PROGRESS AND OPPORTUNITIES

- Completed Registrational and Long Term Clinical Trials
- Pilot Studies Completed
- Potential for Future Development

PoNS® CLINICAL PROGRESS AND OPPORTUNITIES

- Completed Registrational and Long Term Clinical Trials
- Pilot Studies Completed
- Potential for Future Development

Price (March 23/18) CDN$13.17 / US$10.10
52 Week H/L CDN$25.45 / $8.60
Market Cap CDN$274 M / US$210 M
Shares Outstanding 20.8 M

TICKERS

HSM: TSX
Insider Ownership 25%
Ave. Daily Volume (yr) 166,156 (HSM) 26,532 (HSDT)
Cash & Equivalents (Dec. 31/17) US$5.6 M
Debt Nil

HSDT: OTCQB

642 Newtown Yardley Road, Suite 100, Newtown PA 18940 1 877-564-0008 heliusmedical.com

HSM: TSX
HSDT: OTCQB

March 26, 2018
Features of the Portable Neuromodulation Stimulator (PoNS®) Treatment Platform

- Proprietary non-invasive platform for treating symptoms of neurological disease or trauma;
- Direct impulses delivered to the brain and brainstem via disposable mouthpiece placed on the tongue (razor blade), powered by pulse generator;
- In addition to positive registrational trial results in TBI, positive pilot studies support balance and gait disturbance correction, across a range of neurological conditions, including, Multiple Sclerosis (MS) and Stroke and;
- Protected by over 50 US and international patents including proprietary medical methods as well as design and utility of therapeutic delivery mechanisms.

MILESTONES AND CATALYSTS

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2 2018</td>
<td>Contemporaneous submissions to the FDA, Health Canada, TGA in Australia, CE Mark in Europe</td>
</tr>
<tr>
<td>Q3 2018</td>
<td>Clinical Experience Programs begins to potentially drive commercial infrastructure and reimbursement</td>
</tr>
<tr>
<td>H2 2018</td>
<td>Clearance of PoNS device in US, Canada, Australia, Europe</td>
</tr>
<tr>
<td>2018</td>
<td>Potential to generate revenue in 2018</td>
</tr>
</tbody>
</table>

HEALTHCARE TRANSACTION – COMMERCIALIZATION PLATFORM

1. Workers Comp (WC)/Third Party Administrators (TPA) contract with Helius for 14 Week Treatment Unit
2. WC/TPA case managers identify mTBI patients and refers patient and caregivers for presentation of new therapy
3. Helius contracts with PoNS® certified Center of Excellence (COE) - Helius provides PoNS device and training and certification to provide treatment
4. COE provides progress reports to the HCP and bills Helius for services
5. Post FCE performed to determine return to work

PT Center provides treatment

Healthcare Transaction model

LEADERSHIP TEAM PROFILE

Philippe Deschamps
President and CEO; Chairman and Director
• 30+ years in the health sciences industry
• Healthcare Commercialization expertise
• Former CEO at MediMedia Health Marketing
• Former President and CEO at GSW Worldwide (Division of inVentiv Health)
• Former Director of Neuroscience Marketing at Bristol-Myers Squibb

Joyce LaViscount
CFO and COO
• 29 years in the health sciences industry
• Accomplished pharmaceutical/healthcare public company CAO
• Former Executive Director/group controller at Aptalis Pharmaceuticals
• Former Chief Operating Officer and CFO at MM Pharmaceutical Solutions

Jonathan Sackier
Chief Medical Officer
• 30+ years in the health sciences industry
• Trained surgeon and pioneer of new medical technologies
• Has helped build several companies including medical technology, research and product-design and medical contract sales organizations

Forward-Looking Statements: This fact sheet contains forward-looking statements and forward-looking information as such terms are defined under applicable U.S. federal securities and Canadian securities legislation. All statements other than statements of historical fact contained in this fact sheet constitute forward-looking statements and forward-looking information, including, without limitation, statements containing the words “believe”, “may”, “plan”, “should”, “predict”, “potential”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “seek”, “mission”, “goal” and similar words, variations, expressions or the negative thereof. Forward-looking statements are necessarily based on estimates and assumptions, as well as on factors management of the Company believes are appropriate. Forward-looking statements and information in this fact sheet include, but are not limited to statements relating to: the timing of regulatory submissions; the Company’s estimate of the size of the potential markets for its products; the estimated clinical, regulatory and commercial milestones and the timelines for achieving such milestones; the therapeutic benefits, effectiveness; whether the Company will receive, and the timing and costs of obtaining, regulatory clearances in the U.S., Canada, EU and Australia; regulatory developments and the regulatory environments in which the Company operates; and anticipated trends and challenges in the Company’s business and the markets in which it operates.

Said statements reflect management of the Company’s current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others, those risks disclosed in “Risk Factors” above and the risks described in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2017 and our other SEC filings from time to time. This fact sheet speaks as of its date and we, our advisors, and our and their affiliates and representatives undertake no obligation to update, revise or correct the information contained herein, except as required by law.

Industry and Market Data: This fact sheet contains industry and market data that we obtained from independent industry publications. We have not independently confirmed this data and, although we believe it is generally reliable, it involves a number of assumptions and limitations, it is inherently imprecise, and you are cautioned not to place undue reliance on it.